UK markets close in 8 hours 5 minutes

Eckert & Ziegler Strahlen- und Medizintechnik AG (0NZY.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
142.16-0.37 (-0.26%)
As of 4:37PM BST. Market open.
Full screen
Previous close142.53
Open145.42
Bid0.00 x 0
Ask0.00 x 0
Day's range137.04 - 147.20
52-week range137.04 - 147.20
Volume2,541
Avg. volumeN/A
Market cap727.447M
Beta (5Y monthly)0.59
PE ratio (TTM)92.61
EPS (TTM)1.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Eckert & Ziegler: Affiliates Receives Additional NIAID Funding to Advance Pharmaceutical Development

    DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract08.06.2021 / 09:30 The issuer is solely responsible for the content of this announcement.Berlin, 8 June 2021 - Myelo Therapeutics GmbH, an affiliate of Eckert & Ziegler (ISIN DE0005659700, TecDAX) focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Heal

  • EQS Group

    Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

    DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance03.06.2021 / 08:07 The issuer is solely responsible for the content of this announcement.Berlin, 3 June 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States. An agreement to this effe

  • EQS Group

    Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic

    DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Agreement18.05.2021 / 09:14 The issuer is solely responsible for the content of this announcement.Berlin, 18.05.2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed an agreement with Telix Pharmaceuticals (Telix), an Australian-headquartered company, for the exclusive distribution of Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in Germany. Illuccix(R) is a preparation for imaging prostate cancer with positron emission tomography (PET), currently under review for regulatory approval in multiple markets worldwide, including Germany."Illuccix(R) is anticipated to be one of the most important imaging products for prostate cancer. Widespread approval of a preparation for the diagnosis of prostate cancer is urgently needed and we are pleased to have Telix, a pioneer in bringing this drug to market, as a partner," explained Dr Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. "Together with our other products, we will be able to offer nuclear medicine practices and clinics in Germany a fully comprehensive product portfolio for the production of Ga-68 PSMA, once approval has been attained.""We are pleased to have entered this commercial distribution agreement with Eckert & Ziegler so that, subject to German regulatory approval, we will together be able to deliver a commercial product to German patients living with prostate cancer as efficiently as possible. Partnering with such a capable and patient-centric leader in nuclear medicine uniquely aligns with Telix's mission of helping patients with cancer live longer, better quality lives", explained Telix Chief Executive Officer Dr Christian Behrenbruch.Illuccix(R) is offered as a so-called kit preparation for the diagnosis of prostate cancer. For this purpose, Illuccix(R) enables PSMA-11 to be labelled with the radionuclide Ga-68 directly before injection by medical personnel. After preparing the radiopharmaceutical and injecting it into the patient, tumours that show the so-called prostate-specific membrane antigen can be localised by PET.[1],[2]Prostate cancer is the most common type of cancer in men in Germany, with approximately 68,000 cases in 2020, a significantly higher incidence than either lung cancer (38,000 new cases) or bowel cancer (31,000 new cases).[3] Prostate cancer was also the second most common cause of cancer death in men, with over 15,000 men dying from the disease in Germany in 2020. More than 290,000 German men were estimated to be living with prostate cancer in 2020.[1] Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863.[2] Hofman M et al. The Lancet. 2020; 395: 1208-1216.[3] IARC Global Cancer Observatory, 2020.About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.Contributing to saving lives.About Telix PharmaceuticalsTelix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.comAbout Illuccix(R)Telix's lead investigational product, Illuccix(R) (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix(R) in the European Union and Canada. None of Telix's products have received a marketing authorisation in any jurisdiction.Eckert & Ziegler AG Contact:Karolin Riehle, Investor RelationsRobert-Rössle-Str. 10, 13125 Berlin, GermanyTel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.comTelix Pharmaceuticals Contact:Dr. Stewart Holmstrom, Investor RelationsSuite 401, 55 Flemington Road, North Melbourne, VIC 3051, AustraliaEmail: stewart.holmstrom@telixpharma.com18.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: +49 30 941084-138 Fax: +49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1197562 End of News DGAP News Service